Aim: A comprehensive approach was taken in the modern era to develop new distinguished in situ gels, as it has good desirability, sustainability, self-administrative approach and bypassing first pass metabolism. In this context, we developed and designed nasal administrable in situ gel containing anti-epidermal growth factor receptorbody surface area-CYP-solid lipid nanoparticle for glioma treatment. Materials and Methods: After multiple screenings, gellan gum (0.25-0.75%), carbopol 934 (0.20-0.60%), and poloxamer 188 (0.20-0.40%) was taken as developing polymers. Box-Behnken design was used for formulation designing. Almost all the formulation (F1-F17) shown good results. Result and Discussion: The various evaluation parameters for all the formulations such as, viscosity (231 ± 1.22 to 656 ± 1.11 CPs), gelling strength (85 ± 0.9 to 180 ± 0.6 s), pH (5.7 ± 0.06 to 6.2 ± 0.08), gelling temperature (31.34 ± 0.78 to 37.34 ± 0.45°C), gel melting temperature (51.06 ± 0.23 to 55.23 ± 0.65°C), % drug content (94.12 ± 0.4 to 98.87 ± 0.1), spreadability (7.28 ± 0.23 to 10.84 ± 0.45 cm), and mucoadhesive strength (4619.56 ± 0.56 to 6501.86 ± 0.22 dyne/cm 2 ) was been recorded. However, F8 turns out to be an optimized formula as it possess good dissolution profile (86.89% at 12 th h), zero order kinetics (R 2 = 0.9971), maximum desirability factor (D = 0.9921), minimum permeation (9.23% CDP after 720 min study), and maximum skin deposition (91.76%). Further F8 formulation was undergone for stability studies as per ICH Q1A (R 2 ) guideline for 30 days. Conclusion: The results were satisfactory and signify good stability for F8 after 30 days of formulation development. However, further correlative in vivo studies were warranted for more conclusive outcome.
INTRODUCTION
C ompare to conventional dosage form, in situ gels maintain more drug absorption peak and prolong drug residence time. The nasal route is the most significant route of administration as it permits all the compounds than the gastrointestinal tract due to less pH and less enzymatic activity in the nasal cavity. [1] [2] [3] [4] [5] During past decades extensive research on nasal research significantly enhanced due to its numerous advantages. In nasal administration, drug passes through nasal epithelium which helps to pass drugs to systematic circulation than to target site. On the other hand, an olfactory region of nasal cavity passes drugs to cerebrospinal fluids and directly in the brain. [1, [6] [7] [8] As my research formulation is specifically designed for a brain tumor, this in situ nasal administration would be a promising approach toward formulation. Recently, it was confirmed that nasal administration is promising for certain hormones, steroids and low molecular enzymes due to complete absorption within the cavity. Hence, it significantly emphasizes the utilization of nasal route for both local and systematic use. Low viscous in situ gels when sprayed or dripped in the nasal cavity, the polymer reacts with the nasal mucosa to form more viscous
Preparation of anti-EGFR-BSA-CYP-SLNs
The formulation of SLNs of cyclophosphamide was prepared by melting dispersion using selected ingredients followed by a high share homogeneous technique using POLYTRON ® PR 2500E, and ultrasonication (Analab Scientific). The lyophilized product was then conjugated with bovine serum albumin using standard procedures. This conjugated product was further lyophilized and conjugated with anti-EGFR1-Tyr 1175 (0.1 µg/ml) antibody. The desired product was witness impel purification using dialysis (SIGMA-dialysis membrane 12 kDa) and centrifugation at 22000 RPM while maintaining 4°C for 20 min and were stored at 4°C. The final product was lyophilized (pressure of 600 m Torr for 2 h, then at 400 m Torr for 10 h, then at 250 m for 10 h, and 150 motors for 2 h) for 24 h at +20°C temperature ampoules and −110°C condenser temperature. The prepared product was named as anti-EGFR-BSA-CYP-SLNs and ancillary used for making in situ gel.
Development of loaded anti-EGFR-BSA-CYP-SLNs based gel formulation
Optimization of type of gelling agent Different gelling agents (carbopol 934, xanthan gum, sodium alginate, gellan gum, [9] guar gum, poloxamer 188 and HPMC K4M, pectin, carrageenan) were used for the preparation of the in situ based gel. The suitable gelling agent was selected on the basis of their ability to form a good gel and that provide ease of spreadability.
Selection of concentration of polymer for in situ gel
After selecting polymers as a gelling agent, various concentrations of polymers ranging from 0.20% to 0.70% w/v were taken and all the formulations containing various amounts of polymers were evaluated for viscosity and gel forming capacity, from the evaluation parameter concentration range, were selected for further studies.
Preparation of in situ gel formulation
The "cold method" (Schmolka, 1972) was used with slight modification. Accurately weighted 2 mg of lyophilized anti-EGFR-BSA-CYP-SLNs powder was dissolved in sufficient quantity of double distilled water in aseptic condition, which is premix with required quantity of glycerin (humectant) and benzalkonium chloride (preservative). Individually, the varying concentration of polymeric solutions ranges from 0.20% to 0.70% w/v was prepared and kept separately in aseptic condition for 24 h. Further polymeric solutions were added to drug solution proportionately and mix all the excipients (4°C) maintaining constant stirring. The solution was transferred into amber color bottle and refrigerator until a clear solution was formed (6-12 h) [ Figure 1 ]. 
Experimental design

EVALUATION PARAMETER
Drug excipient compatibility studies
Fourier transform infrared (FT-IR) spectroscopy
FT-IR spectroscopy (thermo scientific) was employed to find out the compatibility between prepared SLNs and selected polymers. During compatibility study, gellan gum, carbopol 934, poloxamer 188 were used with lyophilized SLNs.
Differential scanning calorimetry (DSC) study
DSC study of drug and optimized formulation was achieved using Shimadzu DSC 60 analyzer.
Clarity test
In situ gel was evaluated for clarity against dark and white background in the presence of light.
pH evaluation
The prepared in situ gel (1 ml) was diluted into 25 ml of double distilled water and pH of prepared in situ gels solution was recorded using the pH meter (Mettler instrument, Germany) attaining equilibrium for 2 min. Results were reproduced for three times and the average was taken.
Gelling time
By using Shydo model 100, gel timer with stirrer the freshly prepared in-situ gels, gelling time was been detected. In this technique recommended ingredients were placed in a wax free cup and engraved of this cup was fit with gel timer disk. The wire of the disk was adjusted with the motor shift. Start the gel timer by adjusting the stirrer from preventing it from touching in bottom or side of the prepared gel containing cup. After gel timer stopped record the reading on the counter as B.
For gelling time estimation, following formula is inspected.
Gel timing in minutes or second (G) =Mixing or weighing time in second or minutes (A) + Readings from the gel timer in minutes or seconds (B)
Gelation temperature
Gelation temperature is the prerequest for measuring the gelling capacity of in situ gels. Here, modified Miller and Donovan's technique was used. Gelation temperature can be measured by heating the formulations in a 30 ml borosilicate glass tube using stable water bath where per minute temperature was recorded. Required quantities of test tubes were taken and 4 ml of instantly formulated in situ solutions were drained insides of these test tubes, further heat, and gentle stirring is considered untilled solution transformed to gels. Gel formation was considered at a point of temperature when the flow of the prepared gel was fused when test tubes were tilted. [10] The meniscus of gels maintained 90°during invasion. Sol-Gel transformation took place due to higher concentration of polymers in in situ gels.
Gel melting temperature
Gel melting temperature is defined as the temperature at which the slicked gels in 30 ml test tubes again transform to solution on further increase of temperature. This gel-sol occurrence is important to understand the behavior of in situ gel inside of our body.
Drug content study
1 ml in situ gel was diluted in 10 ml of double distilled water. From that solution, 1 ml was withdrawn and poured into the 10 ml volumetric flask. 0.5 ml ferric chloride solution, 0.5 ml of ammonium molybdate solution and 1 ml of hot stannous chloride solution was added which results in the formation of deep blue-colored phosphomolybdate complex. The further solution was diluted up to 10 ml using double distiller water. The colored solution was estimated using SHIMADZU-1880 UV-VIS spectrophotometer at 722 nm.
Viscosity measurement
The viscosity of in situ gel was measured using Brookfield Digital Viscometer (LVDV III Ultra, Brookfield Engineering Laboratories, USA). The final in situ gel was taken into a beaker. [11] The viscosity was measured at 37°C using spinal number 62, at 100 rpm. The final viscosity was been The in situ gel of lyophilized anti-epidermal growth factor receptor-body surface area-CYP-solid lipid nanoparticles powder estimated after 15 min of initiation during cooling period. All the reading was taken in triplicates.
Spreadability study
10 cm length and 4 cm width rectangular glass slide clips with wooden block apparatus. The thread was used to tie up sheep serosal side contains mucous membrane. This everted skin along with this apparatus kept in a hot air oven maintaining 37°C. Two drops of in situ Sol-Gel was place on the mucosal surface at an angel of 120°. The relative distance travelled by the Sol-Gel before its get converted into gel was been measured in cm. Average of three readings was recorded.
Gel strength
50 g f in situ Sol-Gel was taken into 100 ml measuring cylinder. The temperature was maintained up to 37°C which helps accelerated gelation. [12] The relative strength of the gel was determined by measuring the time taken by a weight of 35 g to sink 5 cm inside of this gel.
Mucoadhesive strength
The ex vivo mucoadhesive strength is defined as the force required to detach the formulation from nasal everted mucosal tissue. The everted mucosal membrane was isolated from underlying fats and soft tissues. Further, the membrane had been cleaned using double distilled water and pH 6.4 phosphate buffer solutions. This membrane cuts into two fragments with a diameter of 1 cm 2 each. These two fragments were glued and attached in two of the modified glass slides. In one of the slides, 50 mg in situ gel was spread using glass rod. Slowly inverted slide was placed on the first slide considering inverted and second slide was attached with a modified weighing balance with a thread. The attachment between two slides allows for 2 min. Slowly weights were increased in aright pan of the modified weighing balance, which generates tension within the two slides. [13] The amount of weight or force required to detach the second slide from the first slide is consider the mucoadhesive strength of the prepared in situ gel.
The minimal weight requires to detached mucosal tissues from surface of formulation is called mucoadhesive strength
Where, m = Weight required for detachment in gram, g = Accelerated due to gravity (980 cm/see 2 ) A = Total surface area where mucosa exposed.
In vitro drug release and kinetic study
Dialysis membrane was used for diffusion study. This membrane (LA-393-Mol. Wt. 12, 000-14,000 Daltons, Hi-media, average flat width 29.31 mm, and average diameter 17.5 mm) before mounting in the USP apparatus type II (paddle), the membrane was soaked in ultra-pure boiling distilled water for at least 12 h. The dissolution temperature has to be maintained 37°C ± 0.5°C. The optimized conjugated anti-EGFR-BSA-CYP-SLNs in situ gel (each contents 0.2% w/w of cyclophosphamide) was kept in different bags of dialysis membrane. [9] The dissolution medium was continuously stirred at a speed of around 50 rpm at 37°C ± 0.5°C. With every 1-h interval 5 ml of the sample was withdrawn and 5 ml of fresh phosphate buffer solution was placed inside in receptor compartment (Glass dissolution bowl). Withdrawn 5 ml of each sample was analyzed using SHIMADZU-1880UV-VIS Spectrophotometer at 722 nm (Table 8, Figure 12 ). Dissolution studies were determined by a best fitting method using Higuchi and Korsmeyer-Peppas plots. [14] With the used of linear regression analysis using Microsoft 2010, n and rate constant k were calculated. Coefficient studies (R 2 ) were used for evaluating the accuracy of the fit model. [15, 16] 
Concentration
Ex vivo permeability studies
In-house modified Franz-diffusion cell apparatus was used to study the ex vivo diffusion. The aqueous drug solution of lyophilized SLNs, BSA-CYP-SLNs in situ gel, optimized formula (anti-EGFR-BSA-CYP-SNLs in situ gel), were studied for the permeation through gout everted nasal skin. The receptor area cross section was found to be 4.32 cm 2 . Which is actually filled with double distilled water? The prepared in situ gel placed uniformly on the dorsal side of gout everted nasal skin. Each 1 h of interval 0.5 ml of the sample was removed and immediately replaced with equal volume of double distilled water. The amount of the drug diffused out to the receptor compartment can be determined by SHIMADZU-1880 UV-VIS Spectrophotometer at 722 nm.
Skin deposition study
Immediately after permeation study, the Franz diffusion cell was dismantled after a period of 720 min. The gout nasal everted skin was carefully removed from the diffusion cell. The formulation which stacked into cell membrane mopped properly using phosphate buffer (pH 6.8) and methanol. This cleaning procedure was repeated thrice to ensure no traces of formulation particles left onto the skin surface. The skin was then chopped into pieces and extracted out with methanol for 48 h. Then, it was analyzed by SHIMADZU-1880 UV-VIS Spectrophotometer at 722 nm. The standard calibration curve equation was used to determine how much amount of drug is deposited in the skin [ Figure 2 ].
In vitro gelation study
The ex vivo gelling capacity leveled in three categories on the basis of gelation time and time period for which the formed gel remains.
• + -Gels after few minutes dispersed rapidly • ++ -Gelation immediate remains for few hours consistently • +++ -Gelation immediate remains for prolong period.
Accelerated stability studies
As per the International Conference on Harmonization (ICH) Q1A (R 2 ) guideline, 1 month stability studies were carried out on prepared and optimized anti-EGFR-BSA-CYP-SLNs in situ gel. An adequate quantity of in situ gel was placed inside of a nasal spray bottle and was stored in a small desiccator (Sabar scientific, India) and exposed it in refrigerator maintaining 5°C ± 3°C temperature. Further, the sample was withdrawn periodically for conducting initial, 15 days, 21 days, and 30 days investigation on appearance, pH, gelation temperature, gel melting temperature, % drug content, viscosity, spreadability, and in vitro gelation studies.
RESULT AND DISCUSSION
FT-IR spectroscopy
Compatibility studies of drug polymers are very essential before formulation design. Here, we took lyophilized anti-EGFR-BSA-CYP-SLNs as a drug. FT-IR spectra of lyophilized particles shown characteristic peaks on 3472/cm for N-H stretch, 1484/cm for methylene C-H bend, 1030/cm for C-N primary amine, 715/cm for analiphatic C-Cl stretch, and 895/cm for vinylidene C-H out of the plane bend [ Figure 3 ]. The physical mixture of the drug with various polymers such as gellan gum, carbopol 934, and poloxamer 188 was evaluated [ Figure 4 ]. The various characteristic peaks were 3645/cm for tertiary alcohol O-H stretch, 3480/cm normal polymeric O-H stretch, 2327/cm for S-H stretch, 1702/cm carboxylic acid (RCOOH), 1556/cm for aliphatic -NO 2 , 1028/cm for C-O strong absorption, and 793/cm for C-Cl stretch. The drug spectra and drug and physical mixture spectra show maximum equivalence in respect of web numbers and no significant interaction observed, hence it can be concluded that lyophilized anti-EGFR-BSA-CYP-SLNs were stable with selected polymers, such as gellan gum, carbopol 934, and poloxamer 188.
DSC study
DSC helps to provide useful information about crystallite and amorphism of the prepared sample. The thermal curve of lyophilized anti-EGFR-BSA-CYP-SLNs (drug) shown characteristic peaks on 51.20°C and at 160.84°C. The physical mixture of drug and selected polymer shows thermal peaks on 57.62°C, 147.32°C, and 236.57°C. On the other hand, prepared in situ gel shows characteristic thermal peak at 82.92°C. No significant interaction was observed within drug and prepared in situ gel [ Figure 5 ]. Tables 5 and 6 . The value of P < 0.05 indicates models terms were significant itself.
Plackett and Burman design output
Polynomial equation
Where, Y is predicted response or dependent variables, X 1 , X 2 , and X 3 are independent variables. β 0 consider as intercept. β 1, β 2 , β 3 are linear coefficients. β 12 , β 13 , β 23 is considered as interaction coefficients and β 11 , β 22 , β 33 consider as squared coefficients.
Responses 1 (Y 1 ): Viscosity
Effect of deigned factors on viscosity: After contour plot and 3D surface plot, it was confirmed, that all the factors have significant effects on viscosity. 
Final equation in terms of coded factors
Viscosity (Y 1 )=+541.40+159.75X 1 +69.63X 2 +23.63X 3 +8.25X 1 X 2 +11.75X 1 X 3 +45.00X 2 X 3 −27.20X 1 2 −78.95X 2 2 −63.95X 3 2(2)
Reduced model for viscosity
For viscosity (Y 1 ) coefficient β 12 , β 13, β 22 was found to be insignificant as P value were more than 0.05, hence they were omitted from the full model to generate the reduced model. The high value of correlation coefficient for viscosity designates a good fit for design. On the other hand, calculated F value was found to be less than the tabulated F value which suggested no significant difference between full and reduced model [ Figure 6 ].
Final equation in terms of coded factors after reduced model
A polynomial equation of viscosity was directly indicating that all the three factors have an effect on the viscosity. The viscosity of F1-F17 formulations was found to be increased with increased concentration of polymers. It was noticed that viscosity varies from 231-656 cps for all the formulations. Maximum viscosity was observed in F16, as it is consisting of a maximum concentration of gellan gum and carbopol-934, and minimum viscosity observed in F13 as it comprising less concentration of gellan gum and carbopol-943.
Response 2 (Y 2 ): Gelling strength
Effect of designed factors on gelling strength: After contour plot and 3D surface plot, it was confirmed, that the all the factors have significant effects on gelling strength.
Final equation in terms of coded factors
Gelling strength (Y 2 )=+147.00+27.0X 1 +16.25
Reduced model for gelling strength
For gelling strength (Y 2 ) coefficient β 12 , β 13 was found to be insignificant as P value was more than 0.05, hence they were omitted from the full model to generate the reduced model. The high value of correlation coefficient for gelling strength designate a good fit for design. On the other hand, calculated F value were found to be less than the tabulated F value which suggested no significant difference among full and reduced model [ Figure 7 ]. 
Final equation in terms of coded factors-reduced model
A polynomial equation of gelling strength was directly indicating that all three factors have an effect on the gelling time. The gelling strength of these F1-F17 formulations was found to be increased with increased concentration of polymers. It was noticed that gelling strength varies from 85-180 s for all the formulations. Maximum gelling was observed in F9, as it is consisting of a maximum concentration of gellan gum and carbopol-934, and minimum gelling strength is observed in F13 as it comprising less concentration of gellan gum and carbopol-943.
Response 3 (Y 3 ): %CDR at 1 st h
Effect of deigned factors on Q1: After contour plot and 3D surface plot, it was confirmed, that all the factors have significant effects on %CDR at 1 st h.
Final equation in terms of coded factors
CDR at 1 st h= +26.29−11.72X 1 −5.98X 2 −1.
Reduced model for %CDR at 1 st h (Y 3 )
For coefficients, β 12 ,β 13 , β 11 , β 33 was found to be insignificant as P values were more than 0.05, and hence, they were omitted from the full model to generate the reduced model. The high values of correlation coefficients for viscosity designate a good fit of design. Moreover, calculated F values were found to be less than the tabulated F value which suggested no significant difference between full and reduced model [ Figure 8 ].
Final equation in terms of coded factors
Polynomial equation Y 3 was indicated that all three factors have a negative effect on 1 st h dissolution studies. F1-F17 formulations were found to decrease with increase concentration of polymer. It was observed that Y 3 varies from 12.45 % (F16) to 44.76 % (F13) for all formulations. It indicates immediate drug release was due to the burst effect. Furthermore describe that at initially, proper gelation did not occur and the drug was diffused rapidly through the matrix.
Response 4 (Y 4 ): %CDR at 6 th h
Effect of designed factors on Q1: After contour plot and 3D surface plot, it was confirmed, that all the factors have significant effects on %CDR at the 6 th h.
Final equation in terms of coded factors
CDR at 6 th h = +58.57−11.29X 1 −6.09X 2 −1.16X 3 −0.97
Reduced model for Y 4 For Y 4 coefficients, β 12 , β 13 , β 11 , β 33 was found to be insignificant as P values were more than 0.05, and hence, they were omitted from the full model to generate the reduced model. The high values of correlation coefficients for viscosity designate a good fit of design. Moreover, calculated F values were found to be less than the tabulated F value which suggested no significant difference between full and reduced model [ Figure 9 ].
%CDR at 6 th h (Y 4 )=+58.47−11.29 X 1 −6.09X 2 −1.16X 3 −3.59X 2 X 3 +3.82X 2
(9)
Effect of design factor on Y 4 The experimental design results, contour plot, and 3D surface plot for the 6 th -h %CDR of F1-F17 formulations For Y 5 coefficients, β 12 , β 13 , and β 11 were found to be insignificant as P values were more than 0.05, and hence, they were omitted from the full model to generate the reduced model. The high values of correlation coefficients for viscosity designate a good fit of design. Moreover, calculated F values were found to be less than the tabulated F value which suggested no significant difference between full and reduced model [ Figure 10 ]. formulations. It indicates that in 12 th h dissolution more than 80% amount of drug was dissolved and hear after drug release was decreased gradually. That indicates, there was a little amount of the drug is present in the formulation.
Final equation in terms of coded factors
Experimental design
For designing, we took 17 batches. The various dependent variables are viscosity, gelling strength, %CDR (1 h 
Optimized batch analysis
Contour plots of all dependents variables were overlapped to locate the area of common interest. The optimized batch was selected on the basis of following criteria: Minimum viscosity, minimum gelling strength, and in range drug release. The optimized batch was selected using DESIGN EXPERT trial version 8.0.5 (Stat-Ease. Inc. Minneapolis, USA) and overlay plot was generated [ Figure 11 ]. To confirm the validity of design, the optimized batch was performed and % relative error was calculated which was found to be less than the 9% [ Table 9 ] indicate goodness of fit in the model [ Figure 11 ]. 
Desirability function used to determine optimized batch
To produce the desired product, the formulations responses during optimization, has to combine. It gives us predicting optimum level for independent variables. To produce one desirability function, individual desirability has to be calculated. The optimized parameter to be considered was viscosity, gelling strength, %CDR at a 1 st h, %CDR at the 6 th h, and %CDR at the 12 th h. The best part of this study is no need of specific requirement for gelation temperature of the optimized formulation.
Our target is to find desirability for minimum viscosity for the formulation, hence the following equation to be followed:
Where, U=Upper limit of all the formulation viscosity (656CPs), y=Individual viscosity T=Targeted viscosity as per control chart (303.25 CPs), when y<T, T≤ y ≤U, y>U.
Our next target was to find desirability for minimum gelling strength (d 2 ), hence formula (1) was applied again. Here, U=180 s T= 108.162 s.
%CDR at 1 st h was found to be maximum release before its get maintained.
Desirability factor for %CDR at
When, y<L, L≤ y ≤T, y>T
Where, y=Individual percentage cumulative drug release, L=Lower limit (12.45%)
T=Targeted %CDR at 1 st h (35.812%)
Desirability factor for %CDR at 6 th h (d 4 ) depends on the maximum release of drug from the formulation. Hence, equation 2 was considered for calculation of d 4 . Where L=Lower limit (43.57%) T=Targeted %CDR at 6 th h (67.43%). Desirability factor for %CDR at the 12 th h (d 5 ), again depends on the maximum release of drug from the formulation. Hence, equation 2 was considered for calculation The overall desirability of prepared in situ gel was calculated for all the 17 batches using following equation:
The overall desirability (D) = (d 1 ×d 2 ×d 3 ……d m )
Where, m is the number of responses. The overall desirability value should be below 1 as the range is within 0-1, but the maximum value was to be considered for optimizing batch.
The optimized batch was found to be F8 as it produces maximum D value, that is 0.9921. Hence, optimized polymer concentration are: 0.75% gellan gum, 0.40% carbopol 934, and 0.40% poloxamer 188 ( Table 9) .
Kinetics of drug release
The obtained data from dissolution studies was fitted to various kinetic studies. The purpose of this study is to find the proper kinetic model for optimized batch (F8) and rest of the others.
The coefficient of regression and release rate constant values for zero, first order, Higuchi's and Korsmeyer-Pappas models were compared.
After kinetic studies, it was confirmed that F8 batch maintains proper zero order kinetics, hence F8 was concluded to be the optimized batch ( Figure 13 , Tables 10 and 11 )
Ex vivo permeability study
The best formulation should give minimum permeation and maximum skin deposition. After 720 min permeation study, it is concluded that cyclophosphamide pure drug produces less permeation as it releases almost 101 % of drug within 480 min. Whereas, anti-EGFR-CYP-SLNs in situ gel (F8) produces minimum permeation (9.23% CDP after 720 min study) and maximum skin deposition. Hence, skin deposition study has to be performed.
Skin deposition study results and discussion
The % drug deposition profile showing anti-EGFR-BSA-CYP in situ gel (F8) highest skin deposition compare with the pure drug and optimized SLN. The plain cyclophosphamide showed less accumulation. As per mandatory requirement of ideal formulation, maximum deposition of drug in the squamous epithelium skin and minimum penetration throughout skin is able to release the drug for a prolonged period of time after nasal application. Hence, anti-EGFR-CYP-SLNs in situ gel (F8) was found to be the best candidate for the topical treatment of glioma ( Figure 15 ). to 37.34 ± 0.23, which indicates gelling starts with an exposure of body temperature. The gel-sol transition (melting temperature) of this prepared in situ reaches a higher degree of temperature (51.98 ± 0.34 to 54.98 ± 0.31), which means a good quality of mucoadhesion can be expected. Drug contents of the prepared formulations were found to be within the range of 94.12 ± 0.4 to 98.87 ± 0.1, which indicates uniformity of drug contents and good quality of formulation development. Viscosity increases or decreases with the variation of polymer concentrations. F13 formulation with a minimum concentration of gellan gum and carbopol 934 possess less viscosity (231 ± 1.22 Cps), whereas, F16 with an optimum concentration of gellan gum and carbopol 934 satisfied with a higher viscosity (656 ± 1.11 Cps). The spreadability of the formulation was decreased with the increase of viscosity (4619.56 ± 0.56 for F13 to 6501.86 ± 0.22 for F16). As far as mucoadhesive properties are concerned, it was found that increased gellan gum concentration enhanced mucoadhesion and dissipation property. Good mucoadhesion circumvents first pass metabolism and enhance prolong release activity.
In vitro gelation study indicates that decrease polymer concentration can produce an in situ gel of less physically stable formulations. However, optimized formulation (F8) can extend the physical stability of the formulations for a longer period.
Stability studies
As per ICH Q1A (R 2 ) guideline, 1-month stability study concluded to the optimized finish product-F8. It is maintaining good stability in refrigerator storage. The paired t-test results show P value satisfy the level of significance (<0.001), hence it was concluded that in situ gel is stable in refrigerator storage (Figures 16 and 17, Tables 14 and 15 ).
CONCLUSION
The novelty of this work was to design antiepidermal growth factor and bovine serum albumin conjugated lyophilized nanoparticles of cyclophosphamide in various in situ Sol-Gel formulations. In vitro studies have shown the optimized formulation (F8) dignifies all the evaluation parameters and also passed the stability studies. Further correlative in vivo studies were warranted for more conclusive outcome.
